Local radiation therapy appears beneficial for men with bone metastatic hormone-sensitive prostate cancer (mHSPC).

Patients with metastatic prostate cancer may have improved survival outcomes after undergoing next-generation PSMA PET ...

Nonlinear association seen for effective castration period with metastasis-free survival for any ADT duration.

Bayer said on Monday that it has applied to the EU's drugs regulator for the use of Nubeqa, also known as darolutamide, in ...

In metastatic hormone-sensitive prostate cancer (mHSPC), adding the radioligand 177 Lu-PSMA-617 (Pluvicto) to androgen ...

Berlin: Bayer said on Monday that it has applied to the EU's drugs regulator for the use of Nubeqa, also known as ...

Bayer announced the submission of an application to the European Medicines Agency for the oral androgen receptor inhibitor ...

ORION CORPORATION INVESTOR NEWS 14 OCTOBER 2024 at 11.00 EEST Orion’s collaboration partner Bayer submits application for third indication of darolutamide in the EU Orion’s collaboration partner Bayer ...

Survival after moderate HFRT in patients with high-risk prostate cancer was a secondary outcome of the randomized phase 3 Prostate Cancer Study 5 trial.

A guideline panel indirectly studied cardiotoxicity among advanced prostate cancer treatments (mHSPC, mCRPC, CRPC).

Bayer seeks European approval for darolutamide in combo with ADT in patients with metastatic hormone-sensitive prostate cancer: Berlin Wednesday, October 16, 2024, 13:00 Hrs [IST] ...

Bayer is seeking EMA approval for darolutamide in metastatic hormone-sensitive prostate cancer, building on promising Phase ...